Skip to main content
Figure 4 | BMC Cancer

Figure 4

From: Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype

Figure 4

Additive antitumor activity of dasatinib and Eto in MDA-MB-231 cells. The cells were treated with indicated concentrations of Eto and/or 0.1 μM dasatinib for three days, and the cell count was measured by a Coulter counter as described in the Materials and Methods. Dasatinib additively inhibited the growth of MDA-MB-231 cells. Open circles represent values treated with Eto alone. Closed circles represent values treated with Eto plus dasatinib. The values are expressed as mean ± S.E. of at least two separate experiments.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us